Catenin Beta 1 (Beta Catenin or CTNNB1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Catenin Beta 1 pipeline drugs market research report outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects.
CTNNB1 Pipeline Drugs Market Segmentation by Therapy Areas
The key therapy areas in the CTNNB1 pipeline drugs market are oncology, respiratory, dermatology, gastrointestinal, infectious disease, and non-malignant disorders.
CTNNB1 Pipeline Drugs Market Analysis, by Therapy Areas 2022 (%)
For more CTNNB1 pipeline drugs therapy area insights, download a free report sample
CTNNB1 Pipeline Drugs Market Segmentation by Mechanism of Actions
The key mechanism of actions in the CTNNB1 pipeline drugs market are Catenin Beta 1 Inhibitor and Catenin Beta 1 Activator.
CTNNB1 Pipeline Drugs Market Analysis, by Mechanism of Actions, 2022 (%)
For more CTNNB1 pipeline drugs mechanism of actions insights, download a free report sample
CTNNB1 Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the CTNNB1 pipeline drugs market are oral, intravenous, intratumor, rectal, subcutaneous, and topical.
CTNNB1 Pipeline Drugs Market Analysis, by Routes of Administration, 2022 (%)
For more CTNNB1 pipeline drugs routes of administration insights, download a free report sample
CTNNB1 Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the CTNNB1 pipeline drugs market are small molecule, synthetic peptide, antisense RNAi oligonucleotide, enzyme, antibody, and oligonucleotide.
CTNNB1 Pipeline Drugs Market Analysis, by Molecule Types, 2022 (%)
For more CTNNB1 pipeline drugs molecule type insights, download a free report sample
Competitive Landscape
Some of the leading companies in the CTNNB1 pipeline drugs market are PRISM Pharma Co Ltd, 3+2 Pharma LLC, Agastiya Biotech LLC, Aileron Therapeutics Inc, Circle Pharma Inc, Dicerna Pharmaceuticals Inc, Entrada Therapeutics Inc, f5 Therapeutics Inc, Fog Pharmaceuticals Inc, iBeCa Therapeutics, and MD2 Biosciences Inc.
CTNNB1 Pipeline Drugs Market Analysis, by Companies, 2022 (%)
To know more about the CTNNB1 pipeline drugs companies, download a free report sample
Catenin Beta 1 Pipeline Drugs Market Report Overview
Key Therapy Areas | Oncology, Respiratory, Dermatology, Gastrointestinal, Infectious Disease, and Non-Malignant Disorders |
Analysis Year | 2022 |
Key Mechanism of Actions | Catenin Beta 1 Inhibitor and Catenin Beta 1 Activator |
Key Routes of Administration | Oral, Intravenous, Intratumor, Rectal, Subcutaneous, and Topical |
Key Molecule Types | Small Molecule, Synthetic Peptide, Antisense RNAi Oligonucleotide, Enzyme, Antibody, and Oligonucleotide |
Leading Companies | 3+2 Pharma LLC, Agastiya Biotech LLC, Aileron Therapeutics Inc, Circle Pharma Inc, Dicerna Pharmaceuticals Inc, Entrada Therapeutics Inc, f5 Therapeutics Inc, Fog Pharmaceuticals Inc, iBeCa Therapeutics, and MD2 Biosciences Inc |
CTNNB1 Pipeline Drugs Market MoA Overview ( No of Drugs in the Pipeline, 2022)
- Catenin Beta 1 Inhibitor
- Catenin Beta 1 Activator
CTNNB1 Pipeline Drugs Market RoA Overview ( No of Drugs in the Pipeline, 2022)
- Oral
- Intravenous
- Intratumor
- Rectal
- Subcutaneous
- Topical
CTNNB1 Pipeline Drugs Market Molecule Types Overview ( No of Drugs in the Pipeline, 2022)
- Small Molecule
- Synthetic Peptide
- Antisense RNAi Oligonucleotide
- Enzyme
- Antibody
- Oligonucleotide
Scope
This report provides:
- A snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1).
- Reviews of Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects.
- Assessment of Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- Summaries of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Agastiya Biotech LLC
Aileron Therapeutics Inc
Circle Pharma Inc
Dicerna Pharmaceuticals Inc
Entrada Therapeutics Inc
f5 Therapeutics Inc
Fog Pharmaceuticals Inc
iBeCa Therapeutics
MD2 Biosciences Inc
PRISM Pharma Co Ltd
Propanc Biopharma Inc
Sapience Therapeutics Inc
Stemsynergy Therapeutics Inc
Sumitomo Dainippon Pharma Oncology, Inc
Venn Therapeutics LLC
WntRx Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas of the CTNNB1 pipeline drugs market?
The key therapy areas in the CTNNB1 pipeline drugs market are oncology, respiratory, dermatology, gastrointestinal, infectious disease, and non-malignant disorders.
-
What are the key mechanism of actions in the CTNNB1 pipeline drugs market?
The key mechanism of actions in the CTNNB1 pipeline drugs market are Catenin Beta 1 Inhibitor and Catenin Beta 1 Activator.
-
What are the key routes of administration in the CTNNB1 pipeline drugs market?
The key routes of administration in the CTNNB1 pipeline drugs market are oral, intravenous, intratumor, rectal, subcutaneous, and topical.
-
What are the key molecule types in the CTNNB1 pipeline drugs market?
The key molecule types in the CTNNB1 pipeline drugs market are small molecule, synthetic peptide, antisense RNAi oligonucleotide, enzyme, antibody, and oligonucleotide.
-
Which are the key companies in the CTNNB1 pipeline drugs market?
The key companies in the CTNNB1 pipeline drugs market are 3+2 Pharma LLC, Agastiya Biotech LLC, Aileron Therapeutics Inc, Circle Pharma Inc, Dicerna Pharmaceuticals Inc, Entrada Therapeutics Inc, f5 Therapeutics Inc, Fog Pharmaceuticals Inc, iBeCa Therapeutics, and MD2 Biosciences Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.